Galectin CMO exercises options, sells 568 shares
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised options and sold shares in a routine, pre-planned transaction.
Rhea-AI Filing Summary
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised options and sold shares in a routine, pre-planned transaction. On May 26, 2026, he exercised stock options to acquire 568 shares of common stock at an exercise price of $1.23 per share, then sold 568 shares in open-market trades at a weighted average price of $3.1004 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 2, 2026 and previously disclosed in a Form 10-Q filed on May 15, 2026. Following these transactions, Khurram holds no common shares directly, while remaining stock options cover 40,057 shares at a $1.23 exercise price expiring on January 23, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 568 shares ($1K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Jamil Khurram
Role
Chief Medical Officer
Sold
568 shs ($2K)
Approx. gross sale proceeds
$2K
Approx. exercise cost
$698.64
Approx. pre-tax spread
$1K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 568 | $0.00 | $0.00 |
| Exercise | Common Stock | 568 | $1.23 | $698.64 |
| Sale | Common Stock | 568 | $3.1004 | $2K |
Holdings After Transaction:
Stock option (right to buy) — 40,057 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026
- F2. The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.
Key Figures
Shares sold: 568 shares
Sale price (weighted average): $3.1004 per share
Options exercised: 568 shares
+4 more
7 metrics
Shares sold
568 shares
Common stock sold on May 26, 2026
Sale price (weighted average)
$3.1004 per share
Open-market sale range $3.00–$3.01
Options exercised
568 shares
Common stock acquired via option exercise
Option exercise price
$1.23 per share
Conversion or exercise price for options
Remaining options
40,057 options
Stock options outstanding after transaction
Option expiration
January 23, 2035
Expiration date of option grant
10b5-1 plan adoption date
February 2, 2026
Plan governing the reported sale
Key Terms
Rule 10b5-1 plan, weighted average sale price, stock option (right to buy), open-market sale, +1 more
5 terms
Rule 10b5-1 plan financial
"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price"
stock option (right to buy) financial
"Stock option (right to buy) with an exercise price of $1.23 per share expiring on January 23, 2035"
open-market sale financial
"transaction_action is described as an open-market sale of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Galectin Therapeutics (GALT) CMO Jamil Khurram report in this Form 4?
Jamil Khurram reported exercising stock options for 568 Galectin Therapeutics shares at $1.23 each, then selling 568 common shares at a weighted average of $3.1004 per share. These transactions occurred on May 26, 2026 as disclosed in the Form 4 filing.
What stock options did the Galectin Therapeutics (GALT) CMO exercise in this transaction?
He exercised stock options covering 568 shares of Galectin Therapeutics common stock at a conversion or exercise price of $1.23 per share. These options are part of a larger grant that vests in tranches during 2025 and 2026, as described in the footnotes.
How many Galectin Therapeutics (GALT) stock options remain after this Form 4 transaction?
Following the exercise of 568 options, the Form 4 reports 40,057 stock options remaining. These options carry a $1.23 exercise price and expire on January 23, 2035. Vesting occurs in four installments on specified dates in 2025 and 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
